Kuniyoshi Yasutaka
Department of Social Services and Healthcare Management, International University of Health and Welfare, Otawara, JPN.
Cureus. 2024 Oct 29;16(10):e72668. doi: 10.7759/cureus.72668. eCollection 2024 Oct.
We report a case of persistent lupus anticoagulant (LAC) positivity following mild COVID-19 in a 64-year-old Japanese male with a history of atrial fibrillation. The patient experienced post-COVID-19 condition symptoms, including intermittent fatigue, taste disturbance, and persistent numbness in the upper arm, persistently for over 10 months. Laboratory investigations revealed prolonged activated partial thromboplastin time (aPTT) of 70.0 seconds, positive LAC of 1.5, and positive anti-cardiolipin-beta2-glycoprotein I complex antibody of 4.3 U/mL. This case highlights the potential for long-term LAC positivity after mild COVID-19 and raises questions about its association with post-COVID-19 conditions. The persistence of LAC positivity is noteworthy, as previous studies suggest that virus-induced LAC typically resolves within two to three months. Further research is needed to elucidate the long-term dynamics of LAC in post-COVID-19 condition patients and its clinical implications, particularly in relation to thrombotic complications associated with COVID-19.
我们报告了一例64岁有房颤病史的日本男性,在轻度新型冠状病毒肺炎(COVID-19)感染后狼疮抗凝物(LAC)持续阳性的病例。该患者在感染COVID-19后出现了持续10多个月的症状,包括间歇性疲劳、味觉障碍和上臂持续麻木。实验室检查显示活化部分凝血活酶时间(aPTT)延长至70.0秒,LAC阳性为1.5,抗心磷脂-β2-糖蛋白I复合物抗体阳性为4.3 U/mL。该病例突出了轻度COVID-19感染后长期LAC阳性的可能性,并引发了关于其与COVID-19后状况关联的问题。LAC阳性的持续存在值得注意,因为先前的研究表明病毒诱导的LAC通常在两到三个月内消退。需要进一步研究以阐明COVID-19后状况患者中LAC的长期动态及其临床意义,特别是与COVID-19相关的血栓并发症。